Targeted inhibition of LINC02802 using antisense oligonucleotides significantly restored cisplatin sensitivity in resistant NSCLC cells, suggesting that LINC02802 is a key regulatory factor in the development of drug resistance. Here, LINC02802 is linked to non-small cell lung carcinoma.